Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceplene and Low-dose IL-2 in CMML
NCT03040401Phase 2Unknown
- Sponsor
- Region Västra Götaland
- Start
- Feb 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of histamine dihydrochloride in chronic myelomonocytic leukemia (CMML), sponsored by Region Västra Götaland. Status: unknown.
02
Drugs
histamine dihydrochloride
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03040401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03040401.